阿索尔达治疗

ACOR NASDAQ
7.53
-0.07
-0.92%
盘后: 7.53 0 0.00% 16:23 06/14 EDT
开盘
7.57
昨收
7.60
最高
7.89
最低
7.48
成交量
82.06万
成交均量(3M)
83.92万
52周最高
31.30
52周最低
6.96
换手率
1.71%
市值
3.62亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供阿索尔达治疗 ACOR股票价格,阿索尔达治疗股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on developing therapies that restore function and improve the lives of people with neurological disorders. As of December 31, 2016, the Company marketed three United States Food and Drug Administration (FDA)-approved therapies, including Ampyra (dalfampridine) Extended Release Tablets, 10 milligram (mg), a treatment to improve walking in patients with multiple sclerosis (MS). The Company also markets Zanaflex Capsules and tablets, FDA-approved as short-acting drugs for the management of spasticity, and Qutenza, an FDA-approved dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia, also known as post-shingles pain. The Company has a pipeline of neurological therapies addressing a range of disorders, including Parkinson's disease, migraine and MS. The Company's product candidate, CVT-301, is a self-administered inhaled formulation of levodopa.
展开 >

最近浏览

名称
价格
涨跌幅